Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last4,241 to 4,260 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Intervention vs Control: serious adverse events | 66 of 1,000 37 of 503 | -0.8 points -3.7 to 1.9 | 1,503 | NCT01800201 Automated Hovering to Improve Medication Adherence Among Myocardial Infarction Patients (Heartstrong) |
| 20vPnC vs 13vPnC: serious adverse events | 44 of 1,000 28 of 503 | -1.2 points -3.8 to 1.1 | 1,503 | NCT04379713 20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants |
| Gentamicin Group vs Control Group: Proportion of Patients With Superficial Surgical Wound Infections Based on Centers for Disease Control Criteria Adjudicated by an Independent Blinded Committee. | 49 of 753 46 of 749 | 0.4 points -2.1 to 2.9 | 1,502 | NCT00600483 Safety and Efficacy of an Antibiotic Implant in Cardiac Surgical Subjects at Higher Risk for Sternal Wound Infection |
| Gentamicin Group vs Control Group: Proportion of Patients With Deep Surgical Wound Infections Based on Centers for Disease Control Criteria Adjudicated by an Independent Blinded Committee. | 14 of 753 19 of 749 | -0.7 points -2.3 to 0.9 | 1,502 | NCT00600483 Safety and Efficacy of an Antibiotic Implant in Cardiac Surgical Subjects at Higher Risk for Sternal Wound Infection |
| Gentamicin Group vs Control Group: Rehospitalization for Sternal Wound Infection | 23 of 753 24 of 749 | -0.1 points -2.0 to 1.7 | 1,502 | NCT00600483 Safety and Efficacy of an Antibiotic Implant in Cardiac Surgical Subjects at Higher Risk for Sternal Wound Infection |
| Gentamicin Group vs Control Group: Surgically Treated Surgical Wound Infection Postoperative Day 90 | 25 of 753 37 of 749 | -1.6 points -3.7 to 0.4 | 1,502 | NCT00600483 Safety and Efficacy of an Antibiotic Implant in Cardiac Surgical Subjects at Higher Risk for Sternal Wound Infection |
| Gentamicin Group vs Control Group: Number of Participants With Surgical Wound Infections From Surgery Through Post-operative Day 90 | 63 of 753 65 of 749 | -0.3 points -3.2 to 2.5 | 1,502 | NCT00600483 Safety and Efficacy of an Antibiotic Implant in Cardiac Surgical Subjects at Higher Risk for Sternal Wound Infection |
| Gentamicin Group vs Control Group: deaths from any cause | 19 of 743 27 of 759 | -1.0 points -2.8 to 0.8 | 1,502 | NCT00600483 Safety and Efficacy of an Antibiotic Implant in Cardiac Surgical Subjects at Higher Risk for Sternal Wound Infection |
| Gentamicin Group vs Control Group: serious adverse events | 269 of 743 290 of 759 | -2.0 points -6.9 to 2.9 | 1,502 | NCT00600483 Safety and Efficacy of an Antibiotic Implant in Cardiac Surgical Subjects at Higher Risk for Sternal Wound Infection |
| Empagliflozin vs DPP-4 Inhibitors: Number of Participants With Ketoacidosis | 1 of 751 1 of 751 | 0.0 points -0.6 to 0.6 | 1,502 | NCT03764631 Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration |
| Empagliflozin vs DPP-4 Inhibitors: Number of Participants With Volume Depletion | 6 of 751 7 of 751 | -0.1 points -1.2 to 0.9 | 1,502 | NCT03764631 Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration |
| Empagliflozin vs DPP-4 Inhibitors: serious adverse events | 6 of 751 2 of 751 | 0.5 points -0.3 to 1.5 | 1,502 | NCT03764631 Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration |
| Tecemotide (L-BLP25) + Cyclophosphamide vs Saline + Placebo: serious adverse events | 303 of 1,024 151 of 477 | -2.1 points -7.2 to 2.9 | 1,501 | NCT00409188 Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START) |
| Nimenrix Group vs Mencevax ACWY Group: Number of Subjects With Grade 3 General Symptoms (Solicited and Unsolicited) | 10 of 1,125 1 of 376 | 0.6 points -0.7 to 1.4 | 1,501 | NCT00514904 Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old Subjects |
| Nimenrix Group vs Mencevax ACWY Group: Number of Subjects Reporting Any Serious Adverse Events (SAEs) | 15 of 1,125 7 of 376 | -0.5 points -2.5 to 0.8 | 1,501 | NCT00514904 Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old Subjects |
| Nimenrix Group vs Mencevax ACWY Group: Number of Subjects Reporting Any Unsolicited Symptoms | 198 of 1,125 75 of 376 | -2.3 points -7.2 to 2.1 | 1,501 | NCT00514904 Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old Subjects |
| Nimenrix Group vs Mencevax ACWY Group: serious adverse events | 15 of 1,125 7 of 376 | -0.5 points -2.5 to 0.8 | 1,501 | NCT00514904 Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old Subjects |
| MenACWY-CRM vs MenACWY-PS: serious adverse events | 9 of 950 1 of 550 | 0.8 points -0.2 to 1.6 | 1,500 | NCT00329849 Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age |
| Apixaban vs Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care): Number of Participants With Acute Stroke Event | 0 of 753 6 of 747 | -0.8 points -1.7 to -0.1 | 1,500 | NCT02100228 Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion) |
| Apixaban vs Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care): Number of Participants With All Cause Death | 2 of 753 1 of 747 | 0.1 points -0.5 to 0.8 | 1,500 | NCT02100228 Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion) |
Code
curl "https://conductscience.org/api/comparisons/v1?page=213"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=213
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT01800201-sae",
"title": "Intervention vs Control: serious adverse events",
"summary": "66 of 1000 against 37 of 503; risk difference -0.8 points, 95% interval -3.7 to 1.9; NCT01800201, Automated Hovering to Improve Medication Adherence Among Myocardial Infarction Patients (Heartstrong)",
"record": "/library/comparisons/NCT01800201-sae",
"nct_id": "NCT01800201",
"kind": "serious-adverse-events",
"participants": 1503,
"risk_difference": {
"value": -0.007558648111332,
"lower": -0.03715403034698849,
"upper": 0.01855147235000142
},
"group_1": "66 of 1,000",
"group_2": "37 of 503",
"difference": "-0.8 points",
"interval": "-3.7 to 1.9",
"trial_title": "Automated Hovering to Improve Medication Adherence Among Myocardial Infarction Patients (Heartstrong)"
},
{
"id": "NCT04379713-sae",
"title": "20vPnC vs 13vPnC: serious adverse events",
"summary": "44 of 1000 against 28 of 503; risk difference -1.2 points, 95% interval -3.8 to 1.1; NCT04379713, 20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants",
"record": "/library/comparisons/NCT04379713-sae",
"nct_id": "NCT04379713",
"kind": "serious-adverse-events",
"participants": 1503,
"risk_difference": {
"value": -0.011666003976143147,
"lower": -0.037739098226233544,
"upper": 0.010616601037275134
},
"group_1": "44 of 1,000",
"group_2": "28 of 503",
"difference": "-1.2 points",
"interval": "-3.8 to 1.1",
"trial_title": "20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=214",
"request_id": "IPyuOMYd8bBp-Pv4"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
Open Targets
One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant